Magneto-motive ultrasound imaging using molecular specific nanoparticles

使用分子特异性纳米粒子的磁动力超声成像

基本信息

批准号：
7514590
负责人：
STANISLAV Y EMELIANOV
金额：
$ 34.61万
依托单位：
UNIVERSITY OF TEXAS AT AUSTIN
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-06-01 至 2012-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7514590
关键词：
3-Dimensional Accounting Acoustics Address Age Algorithms American Animal Cancer Model Animal Model Animals Basal Cell Cancer Biological Markers Biomedical Engineering Brain Cancer Etiology Cancerous Cells Cessation of life Characteristics Chemical Engineering Clinical Clinical Engineering Colloids Color Computer software Contrast Media Custom Cutaneous Melanoma Detection Development Dextrans Diagnosis Diagnostic Imaging Discipline of Nuclear Medicine Disease Distant Distant Metastasis Early Diagnosis Epidermal Growth Factor Receptor Evaluation Fine needle aspiration biopsy Frequencies Gastrointestinal tract structure Goals Gray unit of radiation dose Hematogenous Histology Image Imaging Device Imaging Techniques Imaging technology In Vitro Incidence Individual Injection of therapeutic agent International Invasive Investigation Knowledge Label Laboratories Length Life Liver Living Arrangement Localized Lymph Node Dissections Lymphatic Lymphatic Spread Magnetic Resonance Imaging Magnetism Malignant Neoplasms Manuscripts Measures Mechanics Mediating Medicine Methods Micrometastasis Microsurgery Modality Molecular Monitor Monoclonal Antibodies Morbidity - disease rate Motion Names Nanotechnology Negative Axillary Lymph Node Neoplasm Metastasis Neoplasms Normal tissue morphology Operative Surgical Procedures Organ Paper Patients Physical Examination Physiological Positive Lymph Node Positron-Emission Tomography Preparation Primary Neoplasm Principal Investigator Procedures Property Protein Overexpression Publications Publishing Radioisotopes Range Research Research Personnel Resolution Risk Route Science Screening for cancer Sentinel Lymph Node Sentinel Lymph Node Biopsy Signal Transduction Site Skin Skin Cancer Slide Software Design Source Stage at Diagnosis Staging Structure System Techniques Testing Therapeutic Therapeutic Intervention Time Tissue Sample Tissues Title Tracer Ultrasonic Transducer Ultrasonics Ultrasonography United States University of Texas M D Anderson Cancer Center Week Woman Work X-Ray Computed Tomography abstracting austin base bioimaging biomaterial compatibility bone cancer cell cellular imaging concept design desire dextran experience human tissue image processing improved in vivo instrumentation iron oxide lifetime risk lymph nodes magnetic field malignant breast neoplasm melanocyte melanoma member men molecular imaging mouse model nanocrystal nanodevice nanoparticle outcome forecast performance tests professor programs prototype receptor response skills symposium tissue phantom tool tumor

项目摘要

DESCRIPTION (provided by applicant): The incidence of malignant melanoma of the skin the most serious form of skin cancer is increasing faster than that of any other cancer in the United States, and this rising incidence is expected to continue for at least the next 20 years. The prognosis for patients with melanoma is determined by the histology of the primary tumor and by the presence and extent of metastatic disease. Accurate staging at diagnosis is important to assess the prognosis and to determine best therapeutic strategy. The physical examination of regional lymph nodes is often inaccurate. More definitive information about the status of the regional nodes can be obtained from elective lymph node dissection (ELND), lymphoscintigraphy with sentinel node biopsy (LSNB), or fine needle aspiration. However, there are several major drawbacks of these procedures. Although some sites of metastatic disease may be clinically apparent, imaging must be used to detect unsuspected metastases almost all patients who die from melanoma do so with disseminated disease. Imaging studies are, therefore, an important component of the evaluation of patients with both localized and advanced melanoma. However, current imaging techniques including computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET) and ultrasound imaging are ineffective in majority of asymptomatic patients with stage I or II disease. Therefore, there is an urgent and definite clinical need for an objective imaging technique that is widely available, is noninvasive and simple to perform, is safe, and can reliably detect and adequately diagnose early lymph node micro-metastases in real- time. The overall goal of our research program is to develop an in-vivo, minimally noninvasive, molecular specific imaging technology magneto-motive ultrasound (MMUS) imaging capable of immediate and accurate assessment of presence and extent of metastatic disease at all stages. In MMUS imaging, the targeted magnetic iron oxide nanoparticles are injected into the tissue and the ultrasound is used both to visualize the tissue and to accurately evaluate the internal tissue motion induced by the externally applied magnetic field. The central theme of the current application is threefold: to design and build a laboratory prototype of the magneto-motive ultrasound imaging system, to develop molecularly sensitive contrast agent for MMUS imaging system, and to initially test the developed MMUS imaging technology in tissue-mimicking phantoms, 3D cell tissue constructs and, finally, small animal cancer model ex-vivo, in vitro and in vivo. The skin is the largest organ in the body, and it is not surprising that cancer of the skin is the most common of all cancers. Melanoma a cancer that begins in skin cells called melanocytes is the most deadly skin cancer, accounting for 79% of skin cancer deaths. Melanoma is currently the sixth most common cancer in American men and the seventh most common in American women. The median age at diagnosis is between 45 and 55, although 25% of cases occur in individuals before age 40. It is the second most common cancer in women between the ages of 20 and 35, and the leading cause of cancer death in women ages 25 to 30. The overall goal of our research program is to develop an advanced, noninvasive (or minimally invasive), real- time imaging technique magneto-motive ultrasound (MMUS) imaging to assess sentinel lymph node metastases thus identifying the best therapeutic intervention including immediate therapy if necessary.

描述（由申请人提供）：皮肤恶性黑色素瘤的发病率最严重的皮肤癌的增长速度比美国其他任何癌症都快，并且预计至少在未来20年中，这种上升的发病率将持续下去。黑色素瘤患者的预后由原发性肿瘤的组织学和转移性疾病的存在和程度决定。诊断时的准确分期对于评估预后和确定最佳治疗策略很重要。区域淋巴结的体格检查通常不准确。有关区域节点状态的更明确的信息可以从选度淋巴结解剖（ELND），带有前哨节点活检（LSNB）或细针吸入的淋巴镜图（ELND），淋巴镜图。但是，这些程序有几个主要缺点。尽管某些转移性疾病的部位可能在临床上很明显，但必须使用成像来检测几乎所有因黑色素瘤死亡的患者而使用的转移，这与传播性疾病有关。因此，成像研究是评估局部和晚期黑色素瘤患者的重要组成部分。但是，当前的成像技术在内，包括计算机断层扫描（CT），磁共振成像（MRI），正电子发射断层扫描（PET）和超声成像在大多数无症状的I期或II期无症状患者中无效。因此，对广泛可用的客观成像技术有一个紧急且确定的临床需求，无创和易于执行，安全，并且可以在实时可靠地检测并充分诊断出早期淋巴结微型企业。我们的研究计划的总体目标是开发一种体内，微不足道的，分子特异性成像技术磁性超声（MMU）成像，能够立即和准确评估所有阶段转移性疾病的存在和程度。在MMU成像中，将靶向的氧化铁纳米颗粒注入组织中，并使用超声来可视化组织并准确评估由外部施加的磁场引起的内部组织运动。当前应用的中心主题是三重的：设计和建立磁性超声影像系统的实验室原型，开发用于MMU成像系统的分子敏感对比剂，并最初测试已开发的MMU成像技术在组织模拟的幻象中，3D细胞组织结构以及3D细胞组织结构以及最终小型动物癌症模型，并在viv和VIV中进行。皮肤是体内最大的器官，皮肤的癌症是所有癌症中最常见的，也就不足为奇了。黑色素瘤开始于称为黑素细胞的皮肤细胞的癌症是最致命的皮肤癌，占皮肤癌死亡的79％。黑色素瘤目前是美国男性中第六个最常见的癌症，也是美国女性第七最常见的癌症。 The median age at diagnosis is between 45 and 55, although 25% of cases occur in individuals before age 40. It is the second most common cancer in women between the ages of 20 and 35, and the leading cause of cancer death in women ages 25 to 30. The overall goal of our research program is to develop an advanced, noninvasive (or minimally invasive), real- time imaging technique magneto-motive ultrasound (MMUS) imaging to assess sentinel淋巴结转移，因此确定了最佳的治疗干预措施，包括必要时立即治疗。